Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERT in acute necrotizing pancreatitis
NCT07211568Phase 3Not yet recruiting
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Replacement Enzymes
01
Overview
A Phase 3 trial of pancrelipase in acute necrotizing pancreatitis (ANP), pancreatic exocrine insufficiency (EPI), sponsored by Asian Institute of Gastroenterology. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
pancrelipase
03
Conditions
acute necrotizing pancreatitis (ANP)pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT07211568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211568.